Hls Therapeutics Stock Current Valuation
| HLS Stock | CAD 3.51 0.01 0.28% |
Valuation analysis of HLS Therapeutics helps investors to measure HLS Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 4th of December 2024, Enterprise Value Over EBITDA is likely to grow to 15.17. Also, Enterprise Value Multiple is likely to grow to 15.17. Fundamental drivers impacting HLS Therapeutics' valuation include:
Price Book 1.0181 | Enterprise Value 184.8 M | Enterprise Value Ebitda 7.8679 | Price Sales 1.9654 | Forward PE 185.1852 |
Fairly Valued
Today
Please note that HLS Therapeutics' price fluctuation is relatively risky at this time. Calculation of the real value of HLS Therapeutics is based on 3 months time horizon. Increasing HLS Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since HLS Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of HLS Stock. However, HLS Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.51 | Real 3.54 | Hype 3.5 | Naive 3.56 |
The intrinsic value of HLS Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence HLS Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of HLS Therapeutics helps investors to forecast how HLS stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HLS Therapeutics more accurately as focusing exclusively on HLS Therapeutics' fundamentals will not take into account other important factors: HLS Therapeutics Company Current Valuation Analysis
HLS Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current HLS Therapeutics Current Valuation | 184.77 M |
Most of HLS Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HLS Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
HLS Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for HLS Therapeutics is extremely important. It helps to project a fair market value of HLS Stock properly, considering its historical fundamentals such as Current Valuation. Since HLS Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HLS Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HLS Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, HLS Therapeutics has a Current Valuation of 184.77 M. This is 98.71% lower than that of the Pharmaceuticals sector and 97.51% lower than that of the Health Care industry. The current valuation for all Canada stocks is 98.89% higher than that of the company.
HLS Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HLS Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HLS Therapeutics could also be used in its relative valuation, which is a method of valuing HLS Therapeutics by comparing valuation metrics of similar companies.HLS Therapeutics is currently under evaluation in current valuation category among its peers.
HLS Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of HLS Therapeutics from analyzing HLS Therapeutics' financial statements. These drivers represent accounts that assess HLS Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of HLS Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 557.2M | 439.1M | 371.4M | 235.1M | 123.9M | 70.9M | |
| Enterprise Value | 603.3M | 525.6M | 447.8M | 311.8M | 189.6M | 199.0M |
HLS Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 184.77 M | ||||
| Shares Outstanding | 31.79 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 65.15 % | ||||
| Number Of Shares Shorted | 2.75 K | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 1.97 X | ||||
| Revenue | 63.07 M | ||||
| Gross Profit | 50.76 M | ||||
| EBITDA | 21.94 M | ||||
| Net Income | (27.53 M) | ||||
| Cash And Equivalents | 20.72 M | ||||
| Cash Per Share | 1.70 X | ||||
| Total Debt | 87.62 M | ||||
| Debt To Equity | 50.50 % | ||||
| Current Ratio | 1.70 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | 15.79 M | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.97) X | ||||
| Target Price | 4.24 | ||||
| Number Of Employees | 91 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 111.91 M | ||||
| Total Asset | 209.06 M | ||||
| Retained Earnings | (175.46 M) | ||||
| Working Capital | 17.41 M | ||||
| Net Asset | 209.06 M | ||||
| Last Dividend Paid | 0.076 |
About HLS Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLS Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLS Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLS Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against HLS Stock
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.